Investigating outcomes of ablation and therapies for Atrial Fibrillation
Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation
This study is trying to see how well catheter ablation works for people with Atrial Fibrillation and what factors might affect their recovery and health over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1125 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT05504356 on ClinicalTrials.gov |
What this trial studies
VIBRANT-AF is a longitudinal observational study aimed at identifying predictors of effectiveness and complications associated with catheter ablation for Atrial Fibrillation (AF). The study will enroll 15,000 participants who have recently undergone or are scheduled for AF ablation, utilizing the Eureka Research Platform for data collection. Participants will complete weekly surveys regarding their lifestyle habits, AF recurrence, and overall health for one year, while also having the option to use remote ECG monitoring devices. This approach seeks to provide a more comprehensive understanding of real-world outcomes compared to traditional clinical trials.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have recently undergone or are scheduled for catheter ablation for Atrial Fibrillation.
Not a fit: Patients who are unable to consent for themselves or do not have the necessary technology to participate may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of factors influencing the effectiveness of AF ablation, leading to improved patient outcomes.
How similar studies have performed: While there have been studies on AF ablation, this approach utilizing a digital health platform for real-world data collection is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults age 18 and older * Must have a smartphone device (iOS and/or Android) and cell phone number to participate on the mobile app, and will be willing to download the Eureka Research Platform mobile application * Must have email address to participate on the web portal (accessible on any web-connected device) * Undergone a catheter ablation procedure for atrial fibrillation in the week prior to recruitment, or have an ablation planned for within a week from recruitment Exclusion Criteria: * Unable to consent for themselves * Unable to read, speak, comprehend English
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Gregory Marcus, MD, MAS — University of California, San Francisco
- Study coordinator: Bella Peña, BA
- Email: bella.pena@ucsf.edu
- Phone: 415-502-3053
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.